Calendrier des promotions Sol-Gel Technologies Ltd.
Calendrier avancé
Graphique simple
À propos de l'entreprise Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on identifying, developing, and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include Twyneo, a novel, once-daily, non-antibiotic topical cream which has completed Phase III clinical trials for the treatment of acne vulgaris; Epsolay, a once-daily topical cream that has completed Phase III clinical trials for the treatment of papulopustular rosacea; SGT-210, which is in Phase I clinical trial for the treatment of palmoplantar keratoderma; SGT-610, a rare disease for the treatment of Gorlin Syndrome which has completed Phase II clinical trials; and Erlotinib and Tapinarof to treat other rare skin indications. It is also involved in the development of generic topical dermatological drug products. The company has collaboration with Perrigo. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.Paramètres de base
IPO date
2018-01-23
ISIN
IL0011417206
Industry
Pharmaceuticals
Sector
Health Care
Валюта
usd
Валюта отчета
usd
Сайт
Grade
Sous-estimation
Nom | Signification | Grade |
P/S | 2.7 | 6 |
P/BV | 1.08 | 9 |
P/E | 0 | 0 |
Efficacité
Nom | Signification | Grade |
ROA | -26.08 | 0 |
ROE | -31.35 | 0 |
ROIC | 0 | 0 |
Dividendes
Nom | Signification | Grade |
Rendement en dividendes | 0 | 0 |
DSI | 0 | 0 |
Croissance moyenne du dividende | 0 | 0 |
Devoir
Nom | Signification | Grade |
Debt/EBITDA | -0.1264 | 10 |
Debt/Ratio | 0.0365 | 10 |
Debt/Equity | 0.2425 | 10 |
Impulsion de croissance
Nom | Signification | Grade |
Rentabilité Revenue, % | 31.11 | 5 |
Rentabilité Ebitda, % | -65.74 | 0 |
Rentabilité EPS, % | -68.71 | 0 |
paper.price.prices
Prix | Common.min. | Common.max. | Changement | paper.changes_in_industry | paper.changes_in_index | |
common.calendar.number_days.1 | 7.52 $ | 0 $ | 0 $ | 0 % | 0 % | 0 % |
common.calendar.number_days.7d | 6.92 $ | 0 $ | 0 $ | 8.67 % | 0 % | 0 % |
common.calendar.number_days.30d | 7.59 $ | 6.9 $ | 7.52 $ | -0.92 % | 0 % | 0 % |
common.calendar.number_days.90d | 0.43 $ | 0.41 $ | 7.85 $ | 1648.84 % | 0 % | 0 % |
common.calendar.number_days.180d | 0.6302 $ | 0.41 $ | 7.85 $ | 1093.27 % | 0 % | 0 % |
common.calendar.number_days.1y | 0.6584 $ | 0.366 $ | 7.85 $ | 1042.16 % | 0 % | 0 % |
common.calendar.number_days.3y | 6.05 $ | 0.366 $ | 7.85 $ | 24.3 % | 0 % | 0 % |
common.calendar.number_days.5y | 7.9 $ | 0.366 $ | 15.49 $ | -4.81 % | 0 % | 0 % |
common.calendar.number_days.10y | 0.366 $ | 0.366 $ | 17.15 $ | 2054.64 % | 0 % | 0 % |
common.calendar.number_days.ytd | 0.732 $ | 0.41 $ | 7.85 $ | 927.32 % | 0 % | 0 % |
Principaux propriétaires
Entreprises similaires
P/E & P/BV
Gestion d'entreprise
Superviseur | Titre d'emploi | Paiement | Année de naissance |
Dr. Alon Seri-Levy | Co-Founder, CEO & Director | 411k | 1961 (64 année) |
Mr. Gilad Mamlok | Advisor | 367k | 1968 (57 années) |
Dr. Itzik Yosef | Chief Operating Officer | 236k | 1976 (49 années) |
Mr. Moshe Arkin | Executive Chairman of the Board | N/A | 1953 (72 année) |
Prof. David Avnir | Co-Founder | N/A | |
Ms. Tamar Fishman Jutkowitz | VP & General Counsel | N/A | 1976 (49 années) |
Dr. Karine Neimann | VP of Projects & Planning and Chief Chemist | N/A | 1971 (54 année) |
Mr. Eyal Ben-Or | Chief Financial Officer |
Informations sur l'entreprise
Adresse: Israel, Ness Ziona, 7 Golda Meir Street - Ouvrir dans google maps, Ouvrir les cartes yandex
Site web: https://www.sol-gel.com
Site web: https://www.sol-gel.com